BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 26790428)

  • 21. Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format.
    Norman R; Viney R; Aaronson NK; Brazier JE; Cella D; Costa DS; Fayers PM; Kemmler G; Peacock S; Pickard AS; Rowen D; Street DJ; Velikova G; Young TA; King MT
    Qual Life Res; 2016 Mar; 25(3):637-49. PubMed ID: 26342928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The European Organisation for Research and Treatment of Cancer Quality of Life Utility-Core 10 Dimensions: Development and Investigation of General Population Utility Norms for Canada, France, Germany, Italy, Poland, and the United Kingdom.
    Pilz MJ; Nolte S; Liegl G; King M; Norman R; McTaggart-Cowan H; Bottomley A; Rose M; Kemmler G; Holzner B; Gamper EM;
    Value Health; 2023 May; 26(5):760-767. PubMed ID: 36572102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies.
    Sommer K; Cottone F; Aaronson NK; Fayers P; Fazi P; Rosti G; Angelucci E; Gaidano G; Venditti A; Voso MT; Baccarani M; Vignetti M; Efficace F
    Qual Life Res; 2020 Mar; 29(3):815-823. PubMed ID: 31782016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15.
    Hjermstad MJ; Bergenmar M; Bjordal K; Fisher SE; Hofmeister D; Montel S; Nicolatou-Galitis O; Pinto M; Raber-Durlacher J; Singer S; Tomaszewska IM; Tomaszewski KA; Verdonck-de Leeuw I; Yarom N; Winstanley JB; Herlofson BB;
    Support Care Cancer; 2016 Sep; 24(9):3915-24. PubMed ID: 27113466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The EORTC QLU-C10D: the Hong Kong valuation study.
    Xu RH; Wong EL; Luo N; Norman R; Lehmann J; Holzner B; King MT; Kemmler G;
    Eur J Health Econ; 2023 Sep; ():. PubMed ID: 37768519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.
    Pilz MJ; Seyringer S; Al-Naesan I; King MT; Bottomley A; Norman R; Schlosser L; Hell T; Gamper EM;
    Pharmacoecon Open; 2024 May; ():. PubMed ID: 38696019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer.
    Petersen MA; Aaronson NK; Conroy T; Costantini A; Giesinger JM; Hammerlid E; Holzner B; Johnson CD; Kieffer JM; van Leeuwen M; Nolte S; Ramage JK; Tomaszewski KA; Waldmann A; Young T; Zotti P; Groenvold M;
    Qual Life Res; 2020 May; 29(5):1405-1417. PubMed ID: 31955374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.
    Gamper EM; Cottone F; Sommer K; Norman R; King M; Breccia M; Caocci G; Patriarca A; Palumbo GA; Stauder R; Niscola P; Platzbecker U; Caers J; Vignetti M; Efficace F
    J Clin Epidemiol; 2021 Sep; 137():31-44. PubMed ID: 33753228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients.
    Pan CW; He JY; Zhu YB; Zhao CH; Luo N; Wang P
    Eur J Health Econ; 2023 Aug; 24(6):885-893. PubMed ID: 36083356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimation of Health-Related Utilities for
    Soare IA; Leeuwenkamp O; Longworth L
    Pharmacoecon Open; 2021 Dec; 5(4):715-725. PubMed ID: 34260017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychometric Properties of the Fatigue Questionnaire EORTC QLQ-FA12 in a Sample of Female Cancer Patients.
    Kecke S; Ernst J; Einenkel J; Singer S; Hinz A
    J Pain Symptom Manage; 2017 Dec; 54(6):922-928. PubMed ID: 28807705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Test-Retest Reliability of Discrete Choice Experiment for Valuations of QLU-C10D Health States.
    Gamper EM; Holzner B; King MT; Norman R; Viney R; Nerich V; Kemmler G
    Value Health; 2018 Aug; 21(8):958-966. PubMed ID: 30098674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.
    Petersen MA; Aaronson NK; Arraras JI; Chie WC; Conroy T; Costantini A; Dirven L; Fayers P; Gamper EM; Giesinger JM; Habets EJJ; Hammerlid E; Helbostad J; Hjermstad MJ; Holzner B; Johnson C; Kemmler G; King MT; Kaasa S; Loge JH; Reijneveld JC; Singer S; Taphoorn MJB; Thamsborg LH; Tomaszewski KA; Velikova G; Verdonck-de Leeuw IM; Young T; Groenvold M;
    Eur J Cancer; 2018 Sep; 100():8-16. PubMed ID: 29936066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychometric evaluation of an item bank for computerized adaptive testing of the EORTC QLQ-C30 cognitive functioning dimension in cancer patients.
    Dirven L; Groenvold M; Taphoorn MJB; Conroy T; Tomaszewski KA; Young T; Petersen MA;
    Qual Life Res; 2017 Nov; 26(11):2919-2929. PubMed ID: 28707048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Content validation of the EORTC QLQ-C15-PAL with advanced cancer patients and health care professionals from palliative care services in Chile.
    Rojas-Concha L; Hansen MB; Petersen MA; Groenvold M
    BMC Palliat Care; 2020 Jun; 19(1):81. PubMed ID: 32517678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive factors of overall well-being using the EORTC QLQ-C15-PAL extracted from the EORTC QLQ-C30.
    Lam K; Zeng L; Zhang L; Tseng LM; Hou MF; Fairchild A; Vassiliou V; Jesus-Garcia R; Alm El-Din MA; Kumar A; Forges F; Chie WC; Sahgal A; Poon M; Chow E
    J Palliat Med; 2013 Apr; 16(4):402-8. PubMed ID: 23458649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation and comparison of the health-related quality-of-life instruments EORTC QLQ-C30 and SF-36 in assessment of patients with chronic nonmalignant pain.
    Fredheim OM; Borchgrevink PC; Saltnes T; Kaasa S
    J Pain Symptom Manage; 2007 Dec; 34(6):657-65. PubMed ID: 17618079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients.
    Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AK; Tang NL; Chu CM; Hui J; Lee KF; Yu S; Yeo W
    Qual Life Res; 2019 Sep; 28(9):2597-2607. PubMed ID: 31037590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
    Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
    BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the Turkish versions of EORTC QLQ-C30 and BR23 modules in breast cancer patients.
    Demirci S; Eser E; Ozsaran Z; Tankisi D; Aras AB; Ozaydemir G; Anacak Y
    Asian Pac J Cancer Prev; 2011; 12(5):1283-7. PubMed ID: 21875283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.